Local injection of platelet-rich plasma offers a new therapeutic option for the treatment of esophagotracheal fistula: a case report

J Int Med Res. 2024 Jan;52(1):3000605231220874. doi: 10.1177/03000605231220874.

Abstract

Esophagotracheal fistula (ETF), one of the most serious complications in the treatment of esophageal cancer, presents a complex management challenge. Early diagnosis and treatment are crucial to alleviate clinical symptoms and improve the quality of life of patients with ETF. The most commonly used method for treating ETF is esophageal stenting. However, because of the variable location and size of the fistula, stent placement alone sometimes fails to completely close the fistula, and complications such as fracture and displacement of the esophageal stent may occur. Therefore, safer and more effective methods for the treatment of ETF are required. In recent years, the application of bioactive factors to promote human tissue repair and wound healing has increased and achieved good therapeutic results. We herein describe a case in which we performed endoscopic injection of platelet-rich plasma directly into the ETF site and achieved a favorable outcome. This case suggests that local injection of platelet-rich plasma is a novel treatment modality for ETF.

Keywords: Platelet-rich plasma; case report; endoscopic injection; esophageal cancer; esophagotracheal fistula; novel treatment.

Publication types

  • Case Reports

MeSH terms

  • Esophageal Neoplasms* / complications
  • Humans
  • Platelet-Rich Plasma*
  • Quality of Life
  • Tracheoesophageal Fistula* / complications
  • Tracheoesophageal Fistula* / therapy
  • Treatment Outcome